Skip to main content

Acceleron Pharma, Inc. (XLRN)

NASDAQ: XLRN · IEX Real-Time Price · USD
178.75
-0.93 (-0.52%)
At close: Nov 19, 2021 4:00 PM
179.92
1.17 (0.65%)
After-hours:Nov 19, 2021 7:42 PM EST
Market Cap10.85B
Revenue (ttm)112.76M
Net Income (ttm)-254.85M
Shares Out60.70M
EPS (ttm)-4.20
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,021,458
Open179.71
Previous Close179.68
Day's Range178.75 - 178.75
52-Week Range108.82 - 189.99
Beta0.13
AnalystsBuy
Price Target179.10 (+0.2%)
Earnings DateNov 4, 2021

About XLRN

Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers REBLOZYL (luspatercept-aamt), a first-in-class erythroid maturation agent, for the treatment of anemia in adult patients with beta-thalassemia and transfusion-dependent anemia. The company is also developing Sotatercept, an activin receptor type IIA fusion protein, for the treatment of patients with pulmonary arterial hypertension; ACE-1334, a pulmonary therapeutic candida...

IndustryBiotechnology
IPO DateSep 19, 2013
CEOHabib Dable
Employees312
Stock ExchangeNASDAQ
Ticker SymbolXLRN
Full Company Profile

Financial Performance

In 2020, XLRN's revenue was $92.52 million, an increase of 25.04% compared to the previous year's $73.99 million. Losses were -$166.03 million, 33.0% more than in 2019.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for XLRN stock is "Buy." The 12-month stock price forecast is 179.10, which is an increase of 0.20% from the latest price.

Price Target
$179.10
(0.20% upside)
Analyst Consensus: Buy

News

Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck's Inadequate Offer

NEW YORK--(BUSINESS WIRE)--Avoro Capital Advisors (“Avoro”), a long-term and collaborative investor in life sciences and biotechnology companies, together with certain of its affiliates and managed fund...

1 week ago - Business Wire

Is Merck's Planned Acquisition of Acceleron in Trouble?

There's nothing to worry about with a recent delay.

Other symbols:MRK
2 weeks ago - The Motley Fool

Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck's Inadequate Offer

NEW YORK--(BUSINESS WIRE)--Avoro Capital Advisors (“Avoro”), a long-term and collaborative investor in life sciences and biotechnology companies, together with certain of its affiliates and managed fund...

2 weeks ago - Business Wire

Acceleron Pharma (XLRN) Reports Q3 Loss, Lags Revenue Estimates

Acceleron (XLRN) delivered earnings and revenue surprises of 1.04% and -6.62%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

Why Earnings Season Could Be Great for Acceleron Pharma (XLRN)

Acceleron Pharma (XLRN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

3 weeks ago - Zacks Investment Research

SHAREHOLDER ALERT: WeissLaw LLP Reminds DWSN, PAE, XLRN, and FLXN Shareholders About Its Ongoing Investigations

NEW YORK, Nov. 1, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or ...

Other symbols:DWSNFLXNPAE
3 weeks ago - PRNewsWire

Merck Pushes Acceleron Buyout By Refiling For Antitrust Review

Merck & Co Inc (NYSE: MRK) revealed that it had temporarily withdrawn its premerger notification and report form. The company said it plans to refile today.

Other symbols:MRK
3 weeks ago - Benzinga

Earnings Preview: Acceleron Pharma (XLRN) Q3 Earnings Expected to Decline

Acceleron (XLRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 weeks ago - Zacks Investment Research

Avoro Capital Issues Open Letter to Fellow Acceleron Pharma Shareholders

NEW YORK--(BUSINESS WIRE)--Avoro Capital Advisors (“Avoro”), a long-term and collaborative investor in life sciences and biotechnology companies, beneficially owns approximately 7% of Acceleron Pharma I...

4 weeks ago - Business Wire

Acceleron Announces Third Quarter 2021 REBLOZYL® Net Sales

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to...

1 month ago - Business Wire

SHAREHOLDER ALERT: WeissLaw LLP Reminds MDP, GWB, XLRN and HFC Shareholders About Its Ongoing Investigations

NEW YORK, Oct. 22, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or...

Other symbols:GWBHFCMDPMRK
1 month ago - PRNewsWire

Bristol Myers Pledges To Offload Acceleron Shares: Bloomberg

Bristol-Myers Squibb Co (NYSE: BMY) is planning to tender its shares in Acceleron Pharma Inc (NASDAQ: XLRN) after Merck & Co Inc (NYSE: MRK) agreed to buy the biotechnology company for $11.5 billion, Bl...

Other symbols:BMY
1 month ago - Benzinga

Darwin Global Urges Acceleron Shareholders Not to Tender Their Shares to Merck

JERSEY, Channel Islands--(BUSINESS WIRE)--Darwin Global Management Limited (“Darwin Global”), a long-term investor in the biotechnology and pharmaceutical sector and beneficial owner of 2,345,620 shares...

1 month ago - Business Wire

ACCELERON PHARMA ALERT: Investors Should Contact Bragar Eagel & Squire, P.C. Over Tender Offer for XLRN Shares

NEW YORK--(BUSINESS WIRE)-- #Acceleron--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Accelero...

1 month ago - Business Wire

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Acceleron Pharma Inc. - XLRN

NEW YORK, Oct. 13, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action...

1 month ago - PRNewsWire

Holocene Advisors says Merck's offer undervalues Acceleron

Investment management firm Holocene Advisors said it will not tender its shares in Acceleron Pharma Inc into Merck & Co's proposed $180 per share offer for the drugmaker, as it significantly undervalues...

Other symbols:MRK
1 month ago - Reuters

Holocene Advisors Believes Merck's Proposed Offer of $180 Per Share for Acceleron Significantly Undervalues Company

NEW YORK--(BUSINESS WIRE)--Holocene Advisors, LP (“Holocene”), a fundamental investment management firm and significant shareholder of Acceleron Pharma Inc. (Nasdaq: XLRN) (“Acceleron” or the “Company”)...

Other symbols:MRK
1 month ago - Business Wire

Is an Acquisition of Acceleron a Smart Move for Merck?

Merck will pick up a promising pipeline candidate with the deal.

Other symbols:MRK
1 month ago - The Motley Fool

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Merger of Ac...

New York, New York--(Newsfile Corp. - October 4, 2021) -  The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Acceleron Pharma Inc. (NASDAQ: XLRN) ...

1 month ago - Newsfile Corp

With Acceleron Acquisition Merck Stock Is Likely To See A Multiple Revision

Merck yesterday announced that it will acquire Acceleron Pharma - a biopharmaceutical company focused on rare diseases - for $11.5 billion funded in cash and debt. Acceleron has multiple potentially blo...

Other symbols:MRK
1 month ago - Forbes

ACCELERON INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Acceleron Pharma I...

1 month ago - Business Wire

Activist Investor Thinks Merck Undervalues Acceleron Buy

Hours after Merck & Co Inc's (NYSE: MRK) announcement to acquire Acceleron Pharma Inc (NASDAQ: XLRN), one of Acceleron's activist investors isn't happy with the price tag. Related:   Merck Seals Acceler...

Other symbols:MRK
1 month ago - Benzinga

Core PCE Inflation Stays at Record-High in August

Core PCE Inflation Stays at Record-High in August.

Other symbols:MRKREGN
1 month ago - Zacks Investment Research

Merck (MRK) to Acquire Acceleron, Build Rare Disease Portfolio

Merck (MRK) is set to acquire rare diseases-focused company Acceleron Pharma for $11.5 billion and gain access to its promising phase III candidate.

Other symbols:MRK
1 month ago - Zacks Investment Research

Avoro Capital Believes Proposed Acquisition of Acceleron Pharma by Merck Undervalues Acceleron Pharma

NEW YORK--(BUSINESS WIRE)--Avoro Capital, a long-term and collaborative investor in life sciences and biotechnology companies, beneficially owns approximately 7% of Acceleron Pharma Inc. (Nasdaq: XLRN) ...

1 month ago - Business Wire